¼¼°èÀÇ ÄÉÅç¶óÀÌµå ½ÃÀå º¸°í¼­(2025³â)
Ketolides Global Market Report 2025
»óǰÄÚµå : 1691989
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 200 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,426,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,288,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 12,150,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ÄÉÅç¶óÀ̵åÀÇ ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â µ¿¾È ¾ÈÁ¤ÀûÀÎ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2029³â¿¡´Â 4.8%ÀÇ CAGR·Î 40¾ï 4,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ¼ºÀåÀº ÄÉÅç¶óÀ̵åÀÇ R&D Ȱµ¿¿¡ ´ëÇÑ ÅõÀÚ, °¨¿° °ËÁø ÇÁ·Î±×·¥ Áõ°¡, ÀÇ·áºñ ÁöÃâ Áõ°¡, Ç×±ÕÁ¦ °ü¸®¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ÁÖ¿ä µ¿ÇâÀ¸·Î´Â °¨¿°ÁõÀÇ Çõ½ÅÀû Ä¡·á, Ç¥Àû Ä¡·áÁ¦ÀÇ °³¹ß, °¨¿°ÁõÀÇ Áø´Ü ¹× Ä¡·áÀÇ ¹ßÀü, »õ·Î¿î ÄÉÅç¶óÀ̵å·ù Á¦Á¦ÀÇ °³¹ß µîÀÌ ÀÖ½À´Ï´Ù.

°¨¿°¼º ÁúȯÀÇ À¯Çà Áõ°¡´Â ÄÉÅç¶óÀÌµå ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¼¼±Õ, ¹ÙÀÌ·¯½º, °õÆÎÀÌ, ±â»ýÃæ°ú °°Àº º´¿øÃ¼¿¡ ÀÇÇØ À¯¹ßµÇ´Â °¨¿°Àº »ç¶÷¿¡¼­ »ç¶÷À¸·Î Àü¿°µÇ¾î ´Ù¾çÇÑ °Ç°­»óÀÇ ÇÕº´ÁõÀ» À¯¹ßÇÕ´Ï´Ù. °áÇÙ(TB)Àº ÄÉÅç¶óÀ̵åÀÇ °­·ÂÇÑ ¼¼Æ÷ ³» Ȱ¼ºÀÌ Æò°¡µÇ°í ÀÖ´Â °¨¿°ÁõÀÇ ÇÑ ¿¹À̸ç, ÀÌ´Â °áÇÙ Ä¡·á¿¡ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 2¿ù GOV.UK´Â ¿µ±¹ ³» °áÇ٠ȯÀÚ°¡ 2023³â 10.7% Áõ°¡ÇÏ¿© 2022³â 4,380¸í¿¡¼­ 4,850¸íÀ¸·Î Áõ°¡Çß´Ù°í º¸°íÇß½À´Ï´Ù. °áÇÙ°ú °°Àº °¨¿°¼º ÁúȯÀÌ Áö¼ÓÀûÀ¸·Î Áõ°¡ÇÔ¿¡ µû¶ó ÄÉÅä¶óÀ̵带 ºñ·ÔÇÑ È¿°úÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÇコÄÉ¾î »ê¾÷ÀÇ È®ÀåÀº ÄÉÅç¶óÀÌµå ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÇコÄÉ¾î »ê¾÷¿¡´Â ȯÀÚ Ä¡·á, ¿¹¹æ, ÀçȰ, ¿ÏÈ­ÀÇ·á¿¡ ÃÊÁ¡À» ¸ÂÃá ´Ù¾çÇÑ ºÐ¾ß°¡ Æ÷ÇԵ˴ϴÙ. ÇコÄÉ¾î »ê¾÷ÀÌ ¼ºÀåÇÔ¿¡ µû¶ó ÄÉÅç¶óÀ̵åÀÇ ¾ÈÀü¼º°ú È¿´ÉÀ» Æò°¡Çϱâ À§ÇÑ ¿¬±¸, ÀÓ»ó½ÃÇè ¹× ±ÔÁ¦ ÇÁ·Î¼¼½º¸¦ Áö¿øÇÔÀ¸·Î½á ÄÉÅç¶óÀ̵åÀÇ °³¹ß ¹× À¯Åë¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÇコÄÉ¾î »ê¾÷Àº ÄÉÅç¶óÀ̵带 ¾ÈÀüÇϰí È¿À²ÀûÀ¸·Î ȯÀÚ¿¡°Ô Åõ¿©ÇÒ ¼ö ÀÖµµ·Ï º¸ÀåÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 5¿ù ¹Ì±¹ ÇコÄɾî Çùȸ´Â ¹Ì±¹ ³» º´¿ø ¼ö°¡ 2022³â 6,093°³¿¡¼­ 6,129°³·Î Áõ°¡Çß´Ù°í º¸°íÇß½À´Ï´Ù. ÀÌ·¯ÇÑ ÇコÄɾî ÀÎÇÁ¶óÀÇ ¼ºÀåÀº ÄÉÅç¶óÀ̵å·ù¿Í °°Àº Ä¡·áÁ¦ÀÇ Áö¼ÓÀûÀÎ °³¹ß ¹× äÅÃÀ» Áö¿øÇÏ¸ç ½ÃÀå °³Ã´ÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, Äڷγª, ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°¡¤±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷°ú Çõ½ÅÀû ±â¾÷

Á¦32Àå ¼¼°èÀÇ ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´

Á¦34Àå ÃÖ±ÙÀÇ ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀå ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Ketolides, a class of antibiotics within the macrolide group, are derived from erythromycin, a 14-membered macrolide. They are created by replacing the cladinose sugar with a keto-group and incorporating a cyclic carbamate group into the lactone ring structure. Ketolides exert their antibiotic effects by inhibiting protein synthesis, thus impeding the production of essential proteins vital for bacterial maintenance and survival.

The primary drugs falling under the ketolides category include telithromycin, cethromycin, and solithromycin. Telithromycin, a semi-synthetic antibiotic of the ketolide class, is deployed in the treatment of respiratory tract infections. These antibiotics find application in a range of conditions, including bronchitis, pneumonia, sinusitis, tonsillitis, and pharyngitis. They target various microorganisms such as Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Chlamydophila pneumoniae, and Mycoplasma pneumoniae. Ketolides are distributed through diverse channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others.

The ketolides market research report is one of a series of new reports from The Business Research Company that provides ketolides market statistics, including ketolides industry global market size, regional shares, competitors with a ketolides market share, detailed ketolides market segments, market trends and opportunities and any further data you may need to thrive in the ketolides industry. This ketolides market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ketolides market size has grown steadily in recent years. It will grow from $3.22 billion in 2024 to $3.35 billion in 2025 at a compound annual growth rate (CAGR) of 4.1%. The growth in the historic period can be attributed to increasing prevalence of infectious diseases, growing consumption of antibiotics, demand for effective and convenient treatments for infectious diseases, government initiatives.

The ketolides market size is expected to see steady growth in the next few years. It will grow to $4.04 billion in 2029 at a compound annual growth rate (CAGR) of 4.8%. The growth in the forecast period can be attributed to investments in research and development activities for ketolides, growing number of screening programs for infectious diseases, incremental healthcare spending growing awareness of antimicrobial stewardship. Major trends in the forecast period include innovative treatments for infectious diseases, development of targeted therapies, advancements in diagnosis and treatment of infectious diseases, development of new ketolide formulations.

The rising prevalence of infectious diseases is expected to drive the growth of the ketolides market. Infectious diseases, caused by pathogens such as bacteria, viruses, fungi, or parasites, can spread from person to person, leading to a variety of health complications. Tuberculosis (TB) is one example of an infectious disease for which ketolides are being evaluated due to their potent intracellular activity, which is crucial for treating TB. For instance, in February 2024, GOV.UK reported that cases of tuberculosis in England increased by 10.7% in 2023, rising from 4,380 in 2022 to 4,850. As infectious diseases like tuberculosis continue to rise, the demand for effective treatments, including ketolides, is expected to grow.

The expansion of the healthcare industry is expected to drive the growth of the ketolides market. The healthcare industry encompasses various sectors focused on curing, preventing, rehabilitating, and providing palliative care for patients. As the healthcare sector grows, it plays a critical role in the development and distribution of ketolides by supporting research, clinical trials, and regulatory processes to assess their safety and effectiveness. Additionally, the healthcare industry ensures that ketolides are administered securely and efficiently to patients. For example, in May 2023, the American Health Care Association reported an increase in the number of hospitals in the U.S., rising from 6,093 in 2022 to 6,129. This growth in healthcare infrastructure supports the ongoing development and adoption of treatments like ketolides, thereby fueling market expansion.

The leading companies within the ketolides market are strongly committed to pioneering innovative drugs and treatment approaches, with the aim of gaining a competitive edge and maintaining their market position. For instance, AliquantumRx Inc., a US-based biotechnical research company, which, in June 2023, celebrated the approval of a patent by the United States Patent and Trademark Office (USPTO), a key agency under the Department of Commerce. This patent, titled 'salts and polymorphs of cethromycin for the treatment of bacterial and protozoan disease,' pertains to cethromycin, a ketolide antibiotic that demonstrates effectiveness against various infectious diseases caused by both bacteria and protozoa. These conditions encompass malaria, babesiosis, toxoplasmosis, diarrhea, and more. Notably, this newly granted patent significantly expands the possibilities for the use of cethromycin, potentially lowering the barriers to its commercialization and facilitating its application in treating a broader range of diseases.

The ketolides market is witnessing growth, primarily attributed to the increasing prevalence of chronic sinusitis. Chronic sinusitis is characterized by persistent inflammation in the sinus cavities around the nasal passages. Ketolides, a class of antibiotics with immunomodulatory and anti-inflammatory properties, find application in the treatment of various medical conditions. Given that chronic sinusitis involves inflammation of the sinuses, ketolides play a role in mitigating this inflammation and alleviating associated symptoms. For example, data from the US-based Centers for Disease Control and Prevention (CDC) as of January 2022 indicated that approximately 11.6% of adults in the United States had received diagnoses of sinusitis. Consequently, the expanding occurrence of chronic sinusitis serves as a driving force behind the growth of the ketolides market.

Major companies operating in the ketolides market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, GSK PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Shionogi & Company Limited, Dr. Reddys Laboratories Ltd., Taisho Pharmaceutical Co. Ltd., Glenmark Pharmaceuticals Ltd., Zhejiang Yongtai Technology Co. Ltd., Corden Pharma GmbH, Optimer Pharmaceuticals Inc., Vivimed Labs Limited, Wockhardt Ltd., Advanced Life Sciences Holdings Inc.

North America was the largest region in the ketolides market in 2024. The regions covered in ketolides report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the ketolides market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ketolides market consists of sales of solithera and ketek, arylalkyl and macrolactone rings. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ketolides Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on ketolides market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for ketolides ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ketolides market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Ketolides Market Characteristics

3. Ketolides Market Trends And Strategies

4. Ketolides Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Ketolides Growth Analysis And Strategic Analysis Framework

6. Ketolides Market Segmentation

7. Ketolides Market Regional And Country Analysis

8. Asia-Pacific Ketolides Market

9. China Ketolides Market

10. India Ketolides Market

11. Japan Ketolides Market

12. Australia Ketolides Market

13. Indonesia Ketolides Market

14. South Korea Ketolides Market

15. Western Europe Ketolides Market

16. UK Ketolides Market

17. Germany Ketolides Market

18. France Ketolides Market

19. Italy Ketolides Market

20. Spain Ketolides Market

21. Eastern Europe Ketolides Market

22. Russia Ketolides Market

23. North America Ketolides Market

24. USA Ketolides Market

25. Canada Ketolides Market

26. South America Ketolides Market

27. Brazil Ketolides Market

28. Middle East Ketolides Market

29. Africa Ketolides Market

30. Ketolides Market Competitive Landscape And Company Profiles

31. Ketolides Market Other Major And Innovative Companies

32. Global Ketolides Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Ketolides Market

34. Recent Developments In The Ketolides Market

35. Ketolides Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â